Boehringer Ingelheim
For Healthcare Professionals
x

Registration Form

Information you provide when registering will be shared with the account owner  and host and can be used and shared by them in accordance with their Terms and Privacy Policy.

Single IV bolus administration

Metalyse® 25 mg is administered by a single IV bolus over 5 to 10 seconds, eliminating the need for a one-hour infusion, as required for Actilyse®1-3

Metalyse® is quick and easy to use and does not require an 
infusion pump - simplifying preparation, saving time and cost, 
as well as reducing dosing errors*1-5

  • Metalyse® 25 mg comes as one single vial of powder for reconstitution, regardless of patient weight

  • The dosing for Metalyse® 25 mg is simple with only 5
weight-based tiers:

Why is Metalyse® 25 mg quicker and easier to use compared to Actilyse®?

Tenecteplase is a genetically modified version of alteplase. Mutations in the protein sequence increased the specificity of Metalyse® (tenecteplase) to fibrin and made it more resistant to natural inhibitors, which increased its half-life and allowed for shorter treatment duration.6-7

Footnotes

  • IV: intravenous; PAI-1: plasminogen activator inhibitor-1.
  • *
    One of the common contributing factors that led to dosing errors associated with alteplase administration was the infusion pump being programmed incorrectly. Additionally, a single IV bolus administration avoids the interruption of treatment, further reducing dosing errors.
  • †
    Tenecteplase was administrated within 4.5 hours after onset of stroke symptoms, as a weight-tiered bolus dose, based on 0.25 mg/kg by 10 kg steps, for the maximum weight at each tier: < 60 kg, 15 mg tenecteplase; ≥ 60 to < 70 kg, 17.5 mg; ≥ 70 to < 80 kg, 20 mg; ≥ 80 to < 90 kg, 22.5 mg; and ≥ 90 kg, 25 mg.
References
  • 1.
     Metalyse® European Summary of Product Characteristics.
  • 2.
     Menon BK, et al. Lancet 2022;400:161-169.
  • 3.
     Bivard A, et al. Lancet Neurol. 2022;21:520-27.
  • 4.
     Actilyse® European Summary of Product Characteristics.
  • 5.
     Dancsecs KA, et al. Am J Emerg Med. 2021;47:90-94.
  • 6.
     Miller, SE and Warach, SJ. Neurotherapeutics 2023;20:664-678.
  • 7.
     Zhu A, et al. Res Pract Thromb Haemost. 2022;6:e12795.
  • 8.
     Huang X, et al. Stroke 2015;46(12):3543-6.
  • 9.
     Tanswell P, et al. Clin Pharmacokinet. 2002;41(15):1229-45.